vs
Orthofix Medical Inc.（OFIX）与Thermon Group Holdings, Inc.（THR）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Thermon Group Holdings, Inc.的1.5倍（$219.9M vs $147.3M），Thermon Group Holdings, Inc.净利率更高（12.4% vs -1.0%，领先13.4%），Thermon Group Holdings, Inc.同比增速更快（9.6% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $13.1M）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Thermon Group Holdings是全球专业热管理解决方案供应商，主打伴热系统、加热电缆、温控监测设备及相关安装支持服务，服务油气、化工、发电、食品饮料等核心工业领域，业务覆盖北美、欧洲、亚太、拉美等全球主要市场。
OFIX vs THR — 直观对比
营收规模更大
OFIX
是对方的1.5倍
$147.3M
营收增速更快
THR
高出7.7%
2.0%
净利率更高
THR
高出13.4%
-1.0%
自由现金流更多
OFIX
多$3.8M
$13.1M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $147.3M |
| 净利润 | $-2.2M | $18.3M |
| 毛利率 | 71.1% | 46.6% |
| 营业利润率 | 0.2% | 18.1% |
| 净利率 | -1.0% | 12.4% |
| 营收同比 | 2.0% | 9.6% |
| 净利润同比 | 92.4% | -1.3% |
| 每股收益（稀释后） | $-0.05 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXTHR
| Q4 25 | $219.9M | $147.3M | ||
| Q3 25 | $205.6M | $131.7M | ||
| Q2 25 | $203.1M | $108.9M | ||
| Q1 25 | $193.6M | — | ||
| Q4 24 | $215.7M | — | ||
| Q3 24 | $196.6M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $188.6M | — |
净利润OFIXTHR
| Q4 25 | $-2.2M | $18.3M | ||
| Q3 25 | $-22.8M | $15.0M | ||
| Q2 25 | $-14.1M | $8.6M | ||
| Q1 25 | $-53.1M | — | ||
| Q4 24 | $-29.1M | — | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-33.4M | — | ||
| Q1 24 | $-36.0M | — |
毛利率OFIXTHR
| Q4 25 | 71.1% | 46.6% | ||
| Q3 25 | 72.2% | 46.4% | ||
| Q2 25 | 68.7% | 44.1% | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXTHR
| Q4 25 | 0.2% | 18.1% | ||
| Q3 25 | -8.3% | 16.4% | ||
| Q2 25 | -7.9% | 10.8% | ||
| Q1 25 | -25.2% | — | ||
| Q4 24 | -5.3% | — | ||
| Q3 24 | -9.6% | — | ||
| Q2 24 | -12.5% | — | ||
| Q1 24 | -15.6% | — |
净利率OFIXTHR
| Q4 25 | -1.0% | 12.4% | ||
| Q3 25 | -11.1% | 11.4% | ||
| Q2 25 | -6.9% | 7.9% | ||
| Q1 25 | -27.4% | — | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -13.9% | — | ||
| Q2 24 | -16.8% | — | ||
| Q1 24 | -19.1% | — |
每股收益（稀释后）OFIXTHR
| Q4 25 | $-0.05 | $0.55 | ||
| Q3 25 | $-0.57 | $0.45 | ||
| Q2 25 | $-0.36 | $0.26 | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $46.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $538.7M |
| 总资产 | $850.6M | $816.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXTHR
| Q4 25 | $82.0M | $46.9M | ||
| Q3 25 | $62.9M | $29.7M | ||
| Q2 25 | $65.6M | $36.5M | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — | ||
| Q1 24 | $27.0M | — |
总债务OFIXTHR
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXTHR
| Q4 25 | $450.0M | $538.7M | ||
| Q3 25 | $442.5M | $515.2M | ||
| Q2 25 | $458.3M | $509.3M | ||
| Q1 25 | $458.3M | — | ||
| Q4 24 | $503.1M | — | ||
| Q3 24 | $525.9M | — | ||
| Q2 24 | $546.0M | — | ||
| Q1 24 | $570.3M | — |
总资产OFIXTHR
| Q4 25 | $850.6M | $816.7M | ||
| Q3 25 | $832.6M | $778.2M | ||
| Q2 25 | $837.2M | $765.3M | ||
| Q1 25 | $823.1M | — | ||
| Q4 24 | $893.3M | — | ||
| Q3 24 | $867.9M | — | ||
| Q2 24 | $882.0M | — | ||
| Q1 24 | $906.0M | — |
负债/权益比OFIXTHR
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $18.0M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $13.1M |
| 自由现金流率自由现金流/营收 | 7.6% | 8.9% |
| 资本支出强度资本支出/营收 | 4.9% | 3.3% |
| 现金转化率经营现金流/净利润 | — | 0.98× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXTHR
| Q4 25 | $27.7M | $18.0M | ||
| Q3 25 | $12.4M | $7.4M | ||
| Q2 25 | $11.6M | $10.7M | ||
| Q1 25 | $-18.4M | — | ||
| Q4 24 | $23.7M | — | ||
| Q3 24 | $11.7M | — | ||
| Q2 24 | $9.0M | — | ||
| Q1 24 | $-18.6M | — |
自由现金流OFIXTHR
| Q4 25 | $16.8M | $13.1M | ||
| Q3 25 | $2.5M | $4.4M | ||
| Q2 25 | $4.5M | $8.3M | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXTHR
| Q4 25 | 7.6% | 8.9% | ||
| Q3 25 | 1.2% | 3.3% | ||
| Q2 25 | 2.2% | 7.6% | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXTHR
| Q4 25 | 4.9% | 3.3% | ||
| Q3 25 | 4.8% | 2.3% | ||
| Q2 25 | 3.5% | 2.2% | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXTHR
| Q4 25 | — | 0.98× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
THR
| Other | $73.7M | 50% |
| Transferred At Point In Time | $56.1M | 38% |
| Transferred Over Time | $17.5M | 12% |
